RXi Pharmaceuticals Corp. (NASDAQ: RXII), a discovery-stage biopharmaceutical company, is focused on developing and commercializing proprietary therapeutics, based on RNA interference (RNAi), to treat various human diseases. The company aims to leverage RNAi-based technologies across multiple therapeutic areas to initially treat neurological diseases, metabolic diseases and cancer. For further information, visit the Company’s web site at www.rxipharma.com.
- 18 years ago
QualityStocks
RXi Pharmaceuticals Corp. (NASDAQ: RXII)
Related Post
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on DNA Repair Cancer Therapies
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced…
-
QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Lucid-MS Program
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM)…
-
QualityStocksNewsBreaks – American Fusion Inc. (OTC: AMFN) Highlights Texatron Fusion Engine Progress Following IEEE ICOPS Presentation
American Fusion (OTC: AMFN) provided an update after Chief Technology Officer Dr. John Brandenburg presented…